Literature DB >> 19808609

Are shades of gray prognostically useful in reporting myocardial perfusion single-photon emission computed tomography?

Aiden Abidov1, Rory Hachamovitch, Sean W Hayes, John D Friedman, Ishac Cohen, Xingping Kang, Ling De Yang, Louise Thomson, Guido Germano, Piotr Slomka, Daniel S Berman.   

Abstract

BACKGROUND: We have advocated the use of a 5-category "normal," "probably normal," "equivocal," "probably abnormal," and "definitely abnormal" approach to final interpretation of myocardial perfusion single-photon emission computed tomography (SPECT). The prognostic value of expressing levels of certainty compared with a dichotomous normal/abnormal classification or categories for summed stress scores is unclear. METHODS AND
RESULTS: Myocardial perfusion SPECT (MPS) was visually assessed using a standard semiquantitative approach, yielding summed scores that were used for preliminary interpretation using 5 levels of certainty. The interpreter was permitted to then shift the level of certainty in the final interpretation by 1 degree, based on nonperfusion MPS variables and available clinical information. To examine the prognostic value of expressing levels of clinical certainty, we evaluated 20 740 unique consecutive patients who underwent rest Tl-201/stress Tc-99m sestamibi MPS (34.3% vasodilator stress), of whom 845 (4.4%) were lost to follow-up and 1695 were excluded from prognostic analysis due to an early revascularization (<60 days after MPS). The remaining 18 200 patients (59.1% men; age, 65+/-13 years) were followed up for cardiac death for a mean of 2.7+/-1.7 years. During the follow-up, a total of 591 cardiac death events occurred. By univariable analysis, there were substantial differences in the distribution of follow-up cardiac death by the category of clinical MPS certainty. The clinical certainty was found to be an independent multivariable predictor of cardiac death in the study population and better identified patients at increased risk of cardiac death than the approaches based solely on the standard categories of summed perfusion scores or based solely on categories of segmental perfusion scores.
CONCLUSIONS: The use of multicategory reporting of MPS results incorporating nonperfusion MPS results and clinical information enhances risk stratification compared with both a dichotomous normal/abnormal approach or approaches based solely on segmental categories of perfusion scores. Whether this enhanced risk stratification based on the clinical certainty of the MPS interpretation leads to a more effective therapeutic regimen, tailored to the individual patient's need, requires further prospective evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808609     DOI: 10.1161/CIRCIMAGING.108.815811

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  16 in total

Review 1.  Value of coronary CTA in patients with known or suspected CAD and non-diagnostic initial myocardial perfusion testing: current evidence and clinical considerations.

Authors:  Aiden Abidov; Gilbert L Raff
Journal:  J Nucl Cardiol       Date:  2010-12       Impact factor: 5.952

2.  Left main disease diagnosis: The Achilles heel or the great strength of modern cardiac imaging?

Authors:  Aiden Abidov
Journal:  J Nucl Cardiol       Date:  2015-10-30       Impact factor: 5.952

Review 3.  Gated SPECT in assessment of regional and global left ventricular function: major tool of modern nuclear imaging.

Authors:  Aiden Abidov; Guido Germano; Rory Hachamovitch; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

4.  Long-term outcomes following a normal stress myocardial perfusion scan.

Authors:  Seth Uretsky; Alan Rozanski
Journal:  J Nucl Cardiol       Date:  2013-10       Impact factor: 5.952

5.  Predictors of high-risk coronary artery disease in subjects with normal SPECT myocardial perfusion imaging.

Authors:  Rine Nakanishi; Heidi Gransar; Piotr Slomka; Reza Arsanjani; Aryeh Shalev; Yuka Otaki; John D Friedman; Sean W Hayes; Louise E B Thomson; Mathews Fish; Guido Germano; Aiden Abidov; Leslee Shaw; Alan Rozanski; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2015-05-14       Impact factor: 5.952

6.  Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging.

Authors:  Jersey Chen; Reza Fazel; Joseph S Ross; Robert L McNamara; Andrew J Einstein; Mouaz Al-Mallah; Harlan M Krumholz; Brahmajee K Nallamothu
Journal:  JACC Cardiovasc Imaging       Date:  2011-06

7.  Applicability of the appropriate use criteria for SPECT myocardial perfusion imaging in Italy: preliminary results.

Authors:  G Medolago; C Marcassa; A Alkraisheh; R Campini; A Ghilardi; R Giubbini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-15       Impact factor: 9.236

8.  Yield of downstream tests after exercise treadmill testing: a prospective cohort study.

Authors:  Mitalee P Christman; Marcio Sommer Bittencourt; Edward Hulten; Ekta Saksena; Jon Hainer; Hicham Skali; Raymond Y Kwong; Daniel E Forman; Sharmila Dorbala; Patrick T O'Gara; Marcelo F Di Carli; Ron Blankstein
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

9.  5-Year Prognostic Value of Quantitative Versus Visual MPI in Subtle Perfusion Defects: Results From REFINE SPECT.

Authors:  Yuka Otaki; Julian Betancur; Tali Sharir; Lien-Hsin Hu; Heidi Gransar; Joanna X Liang; Peyman N Azadani; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Balaji K Tamarappoo; Guido Germano; Damini Dey; Daniel S Berman; Piotr J Slomka
Journal:  JACC Cardiovasc Imaging       Date:  2019-06-12

10.  Prognostic value of quantitative high-speed myocardial perfusion imaging.

Authors:  Ryo Nakazato; Daniel S Berman; Heidi Gransar; Mark Hyun; Romalisa Miranda-Peats; Faith C Kite; Sean W Hayes; Louise E J Thomson; John D Friedman; Alan Rozanski; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2012-10-12       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.